Pharma Focus Asia
KP - Choose our fully recyclable blister films

Efruxifermin, Novel Therapy Discovered for Nonalcoholic Steatohepatitis (NASH)

Akero Therapeutics, discovered novel Efruxifermin for the treatment of nonalcoholic steatohepatitis (NASH).

Efruxifermin (EFX) also known to be AKR-001, currently being evaluated in the ongoing Phase 2b HARMONY study is the main leading candidate for NASH. EFX is a novel therapy developed to reverse fibrosis, to reduce liver fat and inflammation, increase insulin sensitivity, and improve lipoproteins.

It has the ability to treat complicated, multi-system disease state of NASH together with improvements in lipoprotein risk factors linked to cardiovascular disease, the leading cause of death in NASH patients.

Nonalcoholic steatohepatitis (NASH) is a serious liver disease approximately affecting 17 million Americans. Currently there are no approved treatments for NASH and it is the fastest growing cause of liver transplants and liver cancer in the countries like US and Europe.

NASH generally results in accumulation of fat in the liver causing stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death.

US Food and Drug Administration (FDA) grants breakthrough designation for Efruxifermin for the treatment of nonalcoholic steatohepatitis (NASH).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024